USFDA Approves 'Treprostinil' Injection to Treat Pulmonary Arterial Hypertension
US Food and Drug Administration (USFDA) has given preliminary approval for the Treprostinil injection, which aims to treat pulmonary arterial hypertension. The drug is produced by the subsidiary of Alembic Pharmaceuticals and is expected to be equivalent to Remodulin Injection. Patients with pulmonary arterial hypertension experience high blood pressure in arteries that go from the heart to the lungs.